
Daiichi Sankyo: Quizartinib launched in Europe to treat AML
On August 23, Daiichi Sankyo announced that the European Medicines Agency (EMA) has completed the marketing authorization validation of Quizartinib for the treatment of adults
On August 23, Daiichi Sankyo announced that the European Medicines Agency (EMA) has completed the marketing authorization validation of Quizartinib for the treatment of adults